On Tuesday, Shutterstock , Inc. (NYSE:SSTK) faced a downgrade from Citi from Buy to Neutral, accompanied by a significant reduction in the price target to $2.00 from the previous $8.00. The adjustment comes after Shutterstock disclosed that its drug candidate, known as '154, a CD47/SIRPα blocker, will be discontinued. Despite initial positive Phase 1 responses for the treatment of TP53m AML and HR-MDS, the drug did not show improved overall survival rates when compared to the current azacitidine monotherapy benchmarks. These benchmarks show approximately 10.5-10.6 months survival for AML and about 9-12 months for HR-MDS, while '154 did not meet these outcomes.
The company has announced that it will shift its focus away from oncology to concentrate on developing SL-325, a DR3 antibody aimed at treating inflammatory bowel disease. However, this new direction is not expected to influence the company's share value in the short term, as SL-325 is anticipated to be at least a year away from clinical trials, with an Investigational New Drug application expected in the third quarter of 2025.
Citi acknowledged the management's decision to halt the development of '154, commending the disciplined approach to discontinue a project that was not meeting the necessary benchmarks. The decision to pivot towards a different therapeutic area is seen as a strategic move by Shutterstock's management.
The revised price target of $2.00 reflects Citi's adjusted expectations for Shutterstock's stock value, considering the discontinuation of '154 and the early stage of development for SL-325. The firm has taken into account the projected cash per share in the wake of these recent developments.
Shutterstock's shift in its development pipeline marks a new chapter for the company as it navigates away from oncology and into the field of inflammatory disease treatment. The market will be closely monitoring the progress of SL-325 as the company endeavors to bring this new drug candidate through the necessary regulatory and development milestones in the coming years.
In other recent news, Shutterstock has reported a 5.4% year-over-year increase in its second-quarter revenue, reaching $220 million. This growth was primarily driven by its Data, Distribution, and Services business, which saw a surge of 129%. However, the company's Content business experienced a 9% decline in revenue, falling to $170 million. Needham, while maintaining a Buy rating on Shutterstock, lowered the price target to $55 due to reduced revenue projections for the Content division.
Recent developments include Shutterstock's acquisition of Envato, expected to enhance the Content business and add an estimated $75 million to revenues by 2024. The company also unveiled new GenAI 3D capabilities and a partnership with Databricks, indicating a focus on technological advancements. Despite a downward revision of financial estimates, Needham expressed confidence in the stock's potential for recovery, citing low valuation levels and growth prospects within the DDS segment.
InvestingPro Insights
Despite the recent setback in Shutterstock's drug development pipeline, InvestingPro data reveals some positive financial aspects of the company. As of the last twelve months ending Q2 2024, Shutterstock reported a revenue of $884.84 million USD, with a revenue growth of 4.6%. The company's P/E Ratio (Adjusted) stands at 17.1, suggesting a reasonable valuation relative to its earnings.
InvestingPro Tips highlight that Shutterstock holds more cash than debt on its balance sheet, which could provide financial flexibility as it pivots its focus to developing SL-325. Additionally, the company has raised its dividend for 4 consecutive years, demonstrating a commitment to shareholder returns even in the face of strategic shifts. This is further supported by the current dividend yield of 3.39%, which may appeal to income-focused investors during this transition period.
It's worth noting that Shutterstock is trading near its 52-week low, with the stock price at 60.3% of its 52-week high. This could present an opportunity for investors who believe in the company's long-term potential with its new focus on inflammatory bowel disease treatment.
For readers interested in a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into Shutterstock's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.